GSK (GSK): news on Wednesday 7 October 2026

The 11 stories

Each headline's own score, strongest first. Links go to the publisher.

• +10.0 ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia BioSpace
  ViiV Cabenuva trial meets primary endpoint of superior viral suppression
• +9.3 GSK-owned ViiV succeeds in late-stage trial for HIV therapy Seeking Alpha
  ViiV succeeds in late-stage HIV trial
• +9.2 GSK's long-acting Cabenuva scores win in unsuppressed HIV FirstWord Pharma
  Positive Cabenuva trial win in unsuppressed HIV
• +7.5 GSK celebrates "important insights" from Cabenuva study London South East
  GSK welcomes insights from Cabenuva study
• +6.3 Jefferies keeps Buy rating for GSK stock at GBp 2,500.00 target AD HOC NEWS
  Jefferies keeps Buy rating with 2,500p target
• +5.7 GSK stock: company announces potential USD 750 million multiple myeloma deal AD HOC NEWS
  Potential USD 750m multiple myeloma deal signals pipeline expansion
• +5.3 Why Is GSK (LSE:GSK) Stock Back In Focus This Week After The Nuvalent Agreement? Kalkine Media
  Stock in focus after Nuvalent agreement
• +3.7 ViiV girds data package for Cabenuva in competitive HIV treatment market Fierce Pharma
  ViiV builds data package in competitive market; modestly positive
• −2.5 Why is GSK stock flat today? Seller pressure persists, resistance levels in focus Traders Union
  Flat shares with seller pressure persisting
• +0.8 What Matters Now for GSK plc (LSE:GSK) Amid FTSE 100 Moves? Kalkine Media
  Generic market commentary on GSK amid FTSE moves
• +0.5 GSK Pharma stock heads toward Q2 results after trading window closes AD HOC NEWS
  Preview of Q2 results; purely factual, no new information